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 Plasmodium falciparum remains a major source of global mortality, causing 
nearly 500,000 deaths per year. Although diagnostics have made major improvements in 
recent years, microscopy on blood smears remains the gold standard, with blood-based 
rapid diagnostic tests (RDTs) as the other major player in field tests. However, there 
remain social challenges as well as health concerns associated with taking blood, and 
discovery of an alternate body fluid diagnostic has been an area of major research. 
Previous attempts at urine-based diagnostics have generally suffered from impaired 
sensitivity, particularly among afebrile patients. This is likely to be due to a decreased 
quantity of the antigen being detected (PfHRPII) in urine as compared to plasma. This 
work uses urine and plasma samples collected from patients at a health post in Kpone 
on Sea, Ghana, of which 64% were malaria-positive by microscopy, to examine this 
dilution factor and other correlates of urine PfHRPII detection. The first aim was to detect 
PfHRPII in the urine using Western Blot, dot blot, and ImmunoPCR, and compare these 
to a buffered urine-specific RDT. Of these, ImmunoPCR was the most sensitive, and in 
each subset there was a higher proportion of positive results in febrile patients. The next 
aim was to quantitatively examine the ratio of PfHRPII in plasma versus urine using both 
ELISA and ImmunoPCR techniques, which yielded a geometric mean ratio of 69.0 and 
137.6 respectively. The implication for urine-based diagnostics is that they will require an 
almost 100-fold (or more) increase in sensitivity or sample volume to be viable and 
comparable to the sensitivity of blood-based diagnostics. Thus, our final aim was to 
attempt to rectify this by applying Nanotrap nanoparticle technology to sequester and 
concentrate PfHRPII in 500 microliter aliquots of urine. Although the nanoparticles were 
able to concentrate the protein five or six fold, this was insufficient to counteract the 
dilution from plasma and was much below the theoretical 31-fold increase in protein 
content corresponding to a 31-fold increase in sample volume. Further, this technology 
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was suboptimal for detection in actual patient samples, showing concentration in only 
one sample. Although there is room for increasing sample size and altering composition 
of nanoparticles, to surmount the obstacle of decreased PfHRPII concentration in urine. 
Additionally, due to the high variability in PfHRPII detection in the urine, any adequate 
diagnostic will likely have to go well above and beyond the 100-fold benchmark 
elucidated in this work in order to capture a meaningful proportion of malaria-infected 
patients.  
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Infection with human Plasmodium is an important source of global mortality and 
morbidity, estimated to infect over 200 million people1. Malaria the disease is caused by 
a discrete group of apicomplexan parasites belonging to the genus Plasmodium that are 
transmitted through the bites of the female Anopheles mosquito. There are five major 
species that have been shown to infect humans; P. malariae, P. ovale, P. vivax, P. 
knowlesi, and P. falciparum. Each has a slightly different global distribution, but all are 
located in the tropical belt in which the vectors make their home. Of these, the most 
lethal is P. falciparum, which is mostly concentrated in the African region, although a 
significant number of infections also occur in Southeast Asia2. Although malaria, which 
was introduced with the slave trade, was found throughout the United States, it was 
effectively eliminated in 19513; in modern times, US infections are almost always brought 
back by travelers, rather than being caused by local transmission. The 2013 Malaria 
Surveillance Report by the CDC found 1,727 cases of malaria (mostly imported) were 
reported during 20134. This effective elimination was the result of a wide array of public 
health interventions in the first half of the 20th century, and has been aided by overall 
economic development in the US. Nowadays, malaria is largely a disease found in 
lower-income countries due to lack of appropriate infrastructure and preventative 
measures, and continues to be one of the leading causes of death worldwide, 
particularly in children under 5. In 2015, it is estimated that 438,000 deaths were 
attributable to malaria infection, of which 90% were in sub-Saharan Africa1.  
Reducing the global burden of malaria-induced disease (and eventually 
eradicating it) has been a longtime goal of numerous global health organizations, and 
involves a multipronged approach to block transmission, prevent infection and treatment. 
On a global level, some measure of success has certainly been achieved; in 1900, 
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around 77% of the global population was considered malaria-exposed, whereas in 2010 
only about 50% was exposed5. One of the cornerstones of any disease control scheme, 
both in terms of individual treatment as well as community-level surveillance, is an 
appropriately specific and sensitive diagnostic method – without one, it is impossible to 
track effectiveness of interventions or appropriately target treatment. The majority of 
malaria diagnostics are blood-based, which has been met with resistance in many 
countries for community screening of healthy individuals. The goal of this work is to test 
the hypothesis that urine PfHRPII can be used as a biomarker for clinical or subclinical 
infection. This paper seeks to identify and quantify PfHRPII in plasma and urine to 
compare their abundance and explore novel technologies for concentration of proteins in 
urine, with the long-term goal of contributing valuable information to the burgeoning field 
of urine-based diagnostics.  
Malaria Transmission Cycle and Control 
The complex life cycle of the Plasmodium parasite allows for multiple potential 
checkpoints for control. As mentioned, malaria is transmitted by the female Anopheles 
mosquito, which is considered its definitive host (i.e. the host in which it undergoes 
sexual reproduction). When a female Anopheles mosquito feeds on a human host 
harboring the sexual stages of the malaria – the male and female gametocytes - in the in 
the blood, the gametocytes undergo a process of sexual reproduction, proliferation, 
maturation and development within the mosquito that results in the generation of 
thousands of the infective stage known as the sporozoite. Sporozoites migrate to the 
salivary glands, where they may be transmitted with the next bite. In the human host, 
these sporozoites first migrate to the liver, where they begin division and create meronts. 
Rupturing of meronts releases thousands of merozoites, which invade red blood cells to 
begin the erythrocytic portion of the life cycle, during which malaria symptoms occur. 
Merozoites that invade the RBCs may either form erythrocytic schizonts, generating 
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further merozoites, or differentiate into male and female gametocytes to begin the 
transmission cycle anew with the bite of another Anopheles mosquito6,7. Figure 1 shows 
a schematic representation of this complex lifecycle. 
The importance of the mosquito vector to the maturation and transmission of 
Plasmodium parasites makes them an attractive intervention point for reducing burden of 
disease, and many of the most important contributions to reducing malarial disease have 
come from vector control strategies. Because Anopheles mosquitoes tend to bite at 
night, insecticide-treated nets (ITN) have been found to be effective, reducing parasite 
prevalence by up to ten-fold in one study8 . ITNs work by inhibiting bites through physical 
protection by the mesh of the net as well as harboring pyrethroid insecticides within the 
fabric to repel and kill the mosquitoes entirely9. Indoor residual spraying (IRS) is another 
intervention targeted at reducing mosquito bites and transmission by coating the interior 
of homes with insecticides that kill Anopheles mosquitoes. IRS tends to have more 
community-wide benefits in areas of high coverage, even amongst those whose houses 
were not sprayed, whereas net usage is largely protective only of the particular people 
using the nets10. Both have their drawbacks; nets are sometimes either unintentionally 
misused or purposely utilized for other purposes, and both require some level of upkeep. 
However, they have both contributed greatly to malaria control efforts worldwide. One 
study found ITNs in particular to be the greatest contributor to decreasing the number of 
cases of malaria in Africa between 2010 and 201511. Other studies have shown an 
additive protective effect ITN and IRS in areas where both ITN and IRS interventions 
have been deployed12.  
On the human side of the transmission cycle, mass drug administration (MDA) or 
taking antimalarials prophylactically are also options. Drugs used for mass 
administration include primaquine, pyrimethamine, and chloroquine, among others13. 
Concerns about exacerbating tendencies towards drug resistance in parasites have 
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tempered the use of MDA, but recently MDA has begun to be seen as a potential tool in 
areas approaching eradication. Drawbacks include treatment of women of childbearing 
age by exposing them to unnecessary drugs and treatment of more than 99% of 
population which may be not infected. Currently, the WHO recommends it only be used 
in “ideal” conditions where compliance will be high and elimination is feasible and close 
at hand14, as its effectiveness in more high-transit areas and past six months post-
treatment is uncertain15. Some mathematical models imply that MDA could be used in 
concert with other interventions to drastically reduce transmission16. Regular 
prophylactic consumption of anti-malarials such as chloroquine and mefloquine17 is also 
common, though generally too costly to benefit anyone other than travelers spending 
short, discrete periods of time in endemic areas.  
Malaria Symptoms and Treatment 
 The most prominent symptom of malaria is fever, which in P. falciparum-infected 
patients typically presents 10-15 days after an infectious bite1. Other symptoms include 
headache, joint pain, anemia, vomiting, myalgia, jaundice, diarrhea, and many 
others18,19. Unfortunately, these can be commonly confused with a number of other 
illnesses such as pneumonia in children20,21. P. falciparum is the deadliest of the species 
partly because it causes a much faster spike in parasitemia, and partly because of its 
ability to cause cytoadherence in infected erythrocytes22. P. falciparum is also the only 
malaria species that cytoadheres to the vascular endothelium in the brain, blocking local 
circulation and causing the condition known as “cerebral malaria”, a severe and 
complicated set of clinical manifestations (including delirium and coma) that can cause 
death and lifelong cognitive defects in survivors23. Cerebral malaria is most prevalent in 
children under 5, and even with treatment causes death in 15-20% of cases (without 
treatment, death is virtually inevitable)23.  
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Treatment of malaria is a constantly evolving field, partly driven by drug 
resistance, drug availability and cost. Traditional therapies such as chloroquine and 
sulphadoxine-pyrimethamine cost only a few cents per dose, but rampant resistance has 
rendered them ineffective24. Current approaches center on artemisinin combination 
therapies (ACT), which cost $2.00-$2.50 for an adult dose. Although this seems a 
relatively low price to pay, it represents a large proportion of income for most in the 
poverty-stricken countries where malaria is endemic. In addition, inaccurate assessment 
of disease and provision of unnecessary drugs can also cause significant strain on 
already thinly-stretched health resources in places where these drugs are partly or 
wholly subsidized. This can lead to stock-outs, which may occur in as many as 84% of 
public outlets (as an example from Kenya)25 and may also result in the creation of 
private, for-profit drug vendors that further increase prices, or create opportunities for the 
introduction of counterfeit drugs. Additionally, continued development of resistance has 
created the need for even more costly combinations of drugs. The cost-effective drug of 
choice for any particular area varies depending on local transmission; for example, it 
was found in Tanzania that investing in more costly ACT combinations prevented 
treatment failure, but in other areas this may represent an unnecessary expense26.  
 The challenge in efficient prescription of antimalarials is that symptoms of malaria 
are frequently nonspecific, and clinical presentation may be confused with a variety of 
other diseases. Even a sophisticated clinical algorithm may result in the prescription of 
antimalarials to ~29% of non-malarial cases and neglect up to half of actually malaria-
infected persons27. Another study found that only ~10% of children presenting as febrile 
actually had malaria28. At some health posts, fever is considered enough of a reason to 
prescribe antimalarials even without any confirmatory parasitological diagnosis, making 
this statistic particularly alarming. A study in Uganda determined that while 73% of 
febrile patients received antimalarials, only 35% had positive rapid diagnostic test (RDT) 
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results, and overall appropriate treatment was only 34%29. Economic studies have 
implied that ready access to subsidized, over-the-counter antimalarials vastly increases 
coverage, but that nearly half of such pills wind up in the hands of patients without 
malaria; the overall recommendation was for an additional subsidy for over-the-counter 
diagnostics as an addition to malaria control regimes30. Provision of antimalarials to 
those without malaria is not solely a waste of money; it also increases the likelihood of 
development of resistance in parasites and, when using sulfa drugs, bacteria. . Another 
model showed that the cost-per-life-saved of ACT treatment for children under five years 
of age was $209 with presumptive treatment (based only on fever) and $171 with an 
RDT confirmation of malaria infection31; with several million malaria infections occurring 
in children each year32, this cost differential adds up . Clearly, misdiagnosis and 
inaccurate provision of antimalarials present fiscal challenges in addition to potentially 
perpetuating the advent of resistant strains of parasites with the widespread circulation 
of antimalarials. Thus, having field-implementable, accurate diagnostics is a critically 
important piece for efficient treatment and effective global malaria eradication. 
 
Malaria Diagnostics 
 Traditionally, malaria diagnostics have centered on the use of microscopy to 
identify parasites in blood films during a clinical illness. Although this is still considered 
the “gold standard” in most areas, it is far from a perfect solution. Although microscopy 
has the potential to detect quantities of P. falciparum as low as 50 parasites per 
microliter of blood33, in practice the limit of detection may be higher than 500 parasites 
per microliter of blood34 due to inadequate training, patience or expertise of 
microscopists. Aside from issues with sensitivity, improper use and inadequate training 
may also lead to inflated numbers and over-detection of the parasite. One study 
demonstrated a five-fold over-diagnosis of P. falciparum infection using microscopic 
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techniques compared to an RDT (though this does not address the possibility that the 
RDT was simply not detecting low-level infections)35. Microscopy requires resources that 
are frequently unavailable in the low-resource settings where malaria is endemic, and 
cutting corners for field-adaptable technology can cause specificity to suffer. Field 
microscopy may have a positive predictive value as low as 43.2% as compared to 
“expert” microscopy done with better equipment, in part due to more rudimentary field 
technology36. Quality of training may also be an issue. This limits the efficacy of 
microscopy as a field-implementable test for malaria, and contributes to inaccurate (or 
nonexistent) confirmatory diagnosis in clinical settings. This, as mentioned, is 
problematic due to both extra costs associated with unnecessary treatment as well as 
the burgeoning effects of resistance to anti-malarial drugs, which is exacerbated by over-
prescription.  
The “Rapid Diagnostic Test”, or RDT, is the most prevalent modern-day “rival” to 
microscopy in terms of field-based malaria tests. RDTs function on fairly basic principles: 
the presence of the parasite antigen (usually histidine-rich protein 2, PfHRP2) in the 
blood sample causes an antibody-based reaction that ultimately creates a band on the 
nitrocellulose strip of the diagnostic implement. These fall under the umbrella of “lateral 
flow assays”; other examples include the common pregnancy test or urine Streptococcus 
pneumoniae test. Malaria rapid tests may also include antibodies for aldolase and 
lactate dehydrogenase, allowing for some level of speciation, although mixed infections 
still present problems33. The sensitivity of the best RDTs is 75-99% as compared to 
microscopy, depending on local transmission levels and other factors (such as 
parasitemia)37. These are theoretically easy to use and deploy in a field setting, do not 
require electricity, and are thus more widely usable than microscopy. However, they do 
not provide information on the level of parasitemia and severity of infection, and are 
unable to distinguish mixed infections with multiple species of Plasmodium. There have 
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also been studies citing widespread misinterpretation of bands, including a lack of 
attention to the control band or failure to recognize weak positive bands38.  
Laboratory-based diagnostics such as PCR have thus far been shown to be the 
most sensitive method of detecting parasite in the blood. Although there are a wide 
variety of potential molecular targets, the most commonly used is an 18S ribosomal RNA 
sequence; this has the additional benefit of having multiple (~3) copies per parasite, 
allowing for increased sensitivity over other potential targets. Nested PCR, quantitative 
PCR, and nucleic acid sequence-based amplification are all molecular techniques 
currently in use39. qRT-PCR was found to have an analytical sensitivity of > 20 
parasites/mL, with few false positives and a propensity for detecting infection 3.7 days 
earlier as compared to blood smears40. Currently, some scientists are pushing for 
increased use of these molecular diagnostics in epidemiological studies as a method of 
detecting submicroscopic and asymptomatic reservoirs of parasite that may be 
contributing significantly to transmission, particularly in low-transmission areas that are 
nearing elimination39,41. However, none of these techniques are easily field-
implementable, as they require refrigerated items and electricity to be run.  
Enzyme-linked Immunosorbent Assays (ELISAs ) are also considered a validated 
malaria diagnostic42, although they face this common pitfall of requiring lab equipment 
(i.e. a plate reader). Most ELISAs detect the presence of parasite proteins such as 
histidine-rich protein 2 (known as PfHRP2, to be discussed later), which is secreted by 
the P. falciparum parasite during all stages. PfHRP2 is specific (of the human malarias) 
to P. falciparum, though some versions of the diagnostic target proteins such as aldolase 
and lactate dehydrogenase that occur in other species as well, allowing for speciation. 
CelLabs43 manufactures a specific PfHRP2 ELISA kit that may be used for diagnostic 
purposes, with an approximate limit of detection of about 100-1,000 picograms of 
PfHRP242,44,45. Although in some comparative studies this has been shown to outperform 
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microscopy46 and near the performance of qPCR, other studies have placed the overall 
sensitivity at about that of a rapid diagnostic test, or RDT44. Tests for antibodies to 
malaria may also be done, though they are uncommon in the context of diagnosing 
clinical malaria due to the amount of time it takes to mount an antibody response.  
Additionally, there has long been a desire to develop a diagnostic utilizing fluids 
other than blood. There tends to be more resistance to collection of blood samples, and 
in the case of co-infections with other diseases (such as HIV), exposure to blood on the 
part of field staff may present risk of exposure and transmission, especially with 
inadequate gloves and protective equipment. One common negative association and 
source of resistance to the RDT is that blood tests are equated with HIV tests, which 
carry a great amount of stigma47. Other sources cite local religious beliefs that blood is 
sacred as major social factors for eschewing the RDT38. Although the use of the finger 
sticks has become fairly widespread and has gained traction in communities, finding an 
alternative option would be ideal.  
Past attempts to use other, more easily collected, bodily fluids (such as urine) 
have met with limited success. It has long been known that proteins associated with 
Plasmodium infection can be found in the urine; rudimentary studies as early as 1991 
have detected up to 19 different malarial proteins in the urine48. In 2004, the first 
attempts to use urine for malarial diagnosis attempted to apply urine directly to an RDT 
designed for blood (in this case, the ParaSight-F test); it suffered from low sensitivity 
(81%) and very low specificity (26%)49. One of the problems with this application was 
that the low pH of urine interferes with antibody-antigen binding, thus hampering the 
functioning of the RDT. In addition, the concentration of these malarial proteins is likely 
to be much lower in the urine than in the bloodstream. Overall protein content of plasma 
is generally 400 times higher than that of urine50. This presents significant challenges for 
maintaining sensitivity of any diagnostic implement, as even with high levels of blood 
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PfHRP2 we may see moderate or low levels of PfHRP2 in urine. The Urine Dipstick test 
designed by Fyodor, for example, also operates on the basis of detection of PfHRP2, 
and when evaluated in 2014 had only moderate sensitivity compared with a blood smear 
(although it did address the pH issue by incorporating a buffer into the test). Overall 
sensitivity was found to be 83.75%, but for infections with a parasite density less than 
200 parasite/microliter, this dropped to 50%51. This is problematic, because any 
adequate malaria elimination strategy will need to find all potential sources of parasite in 
the population (i.e. even those with lower parasitemia) in order to eliminate potential 
reservoirs. Even at an individual clinical level, the WHO threshold for adequate malaria 
diagnostics is 75% sensitivity for 200 parasites per microliter, and the current Dipstick 
test fails to make the cut52.  
 
HRP2 
Most of our modern diagnostics focus on finding PfHRP2 in assorted body 
liquids. As such, it is important to understand PfHRP2 as a protein. PfHRP2 is, as the 
name suggests, abundant in histidine as well as alanine with numerous repetitive 
epitopes and B-cell epitopes that allow for easy antigen capture using antibody-based 
techniques. It is about 29 kilodaltons in size, but frequently runs as a dimer on SDS gels. 
It is considered a good candidate for a biomarker of malarial infection because it is 
present in the blood regardless of the location of the parasite, and is synthesized and 
excreted by the parasite in multiple of its lifecycle stages in the human host, although 
most is released in schizont rupture53,54. This also means that it may be more 
representative of total parasite biomass, including sequestered parasites, as secretion is 
not limited to circulating parasites55. 
PfHRP2 also has a long half-life, which is both a blessing and a curse. On the 
one hand, it is relatively sturdy and does not degrade easily, because of rare protease 
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sites and easier to find in the urine (and in samples that may have been freeze-thawed 
repeatedly). Indeed the ParaSight F test was used to diagnose malaria in mummies. 
However, its persistence in the blood stream also makes post-treatment diagnosis 
difficult; even if the parasites themselves have all been eliminated, PfHRP2 may linger 
for multiple weeks, creating false positives (or making it impossible to determine whether 
or not all parasites were truly killed)33,56.  
There is also some controversy over correlating levels of PfHRP2 with 
parasitemia. One study examined different parasite isolates and found a wide range of 
secreted protein levels even when controlling for parasitemia, finding little correlation 
between initial blood parasitemia and protein concentrations for Colombian isolates57. 
This, the authors claimed, ran counter to previous data on isolates from Thailand which 
found high correlation between parasitemia and PfHRP2 levels54,55. This may be partly 
because the Colombian study relied on parasitemia gleaned from blood films and may 
not have taken into account the sequestered biomass, as was done in the studies using 
Thai samples. Thus far, the general consensus is that PfHRP2 is unlikely to be well-
correlated with circulating parasitemia58, though this may be points in its favor as it more 
accurately represents the sequestered biomass which tends to cause clinical 
complications.  
In addition, a number of studies have examined the clinical utility of quantified 
PfHRP2 determination in predicting clinical outcomes. High levels of PfHRP2 have been 
associate with cerebral malaria (possibly via heightened PfHRP2 levels in cerebrospinal 
fluid)59, severity of malarial illness in adults55 and severity of malaria, depth of coma, and 




The future of malaria diagnostics  
 Malaria continues to be a hot topic in global health circles, both within the 
laboratory-based community and outside. There is significant pressure to increase the 
sensitivity of existing diagnostics in order to more accurately discover asymptomatic and 
submicroscopic carriers of the parasite (which may continue to impede total eradication) 
as well as devise novel mechanisms to test alternative body fluids. In an ideal world, a 
malaria diagnostic that did not involve a finger stick would be available that could be 
done and accurately interpreted in the home, by the patients themselves.  
 As evidenced by the inadequacy of previous attempts at urine-based diagnostics, 
there is some level of dilution and potentially degradation that occurs during the 
processing of blood. A major question that still needs to be answered, however, is this: 
How much more dilute can we expect urine samples to be? Although there is data for 
overall protein content of blood versus urine, it is unclear whether this will directly 
translate for PfHRP2, particularly given potential increases in protein shedding during 
severe malarial episodes. In order to understand the “hurdle” that must be jumped, it is 
important to have a quantitative notion of how much more sensitive tests must be to be 
viable in urine. To this end, this study utilizes both ImmunoPCR techniques (previously 
used to examine PfHRP2 in cerebrospinal fluid59) and a PfHRP2-specific ELISA kit43 to 
compare matched samples of plasma and urine from febrile patients in Ghana.  
 The question then becomes how we might specifically concentrate PfHRP2 from 
body fluids to enable greater sensitivity. Collaborators at George Mason University have 
previously demonstrated viable “Nanotrap” technology to address this problem The 
Nanotrap technology is a buoyant, porous “smart” nanoparticle containing a novel high-
affinity chemical bait that will rapidly harvest solution-phase analytes, protect the 
captured molecules from degradation, and exclude high abundance unwanted large 
proteins, within minutes, in one step60,61. The porosity of the nanoparticles can be rapidly 
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switched under physiologic conditions. The chemical baits, immobilized in the core of the 
nanoparticles are a previously unexplored class of modified organic molecule dyes that 
bind molecules with extremely high affinity (KD <= 10-13 M) and a very low off-rate62. 
Upon contact with the biofluid sample, the suspended nanoparticles immediately affinity-
sequester desired biomarkers away from albumin, fully protect the biomarkers from 
degradation during processing (even at elevated temperatures), and massively 
concentrate the sequestered biomarkers. The technology can dramatically 
(demonstrated up to 10,000 fold) improve the lower limits of detection and the precision 
quantification by any analytical method61,63,64. To date, successful diagnostics have been 
made for both Lyme disease65 and Chagas disease66 using this technology. We sought 
to optimize the Nanotrap particles for the concentration of PfHRPII and test their efficacy 
with both spike-ins of recombinant protein as well as patient samples.  
 
Hypothesis: Urine PfHRPII can be optimized as a biomarker for malaria detection. 
 
Goal: Characterize the amount of PfHRPII in a group of Ghanaian urine samples in 
order to improve urine malaria detection. 
 
Aim 1: Detect urine PfHRPII by Western Blot and dot blot to compare to previous 
testing.  
Aim 2:Determine the ratio of PfHRPII protein present in plasma versus urine of infected 
patients using ELISA and ImmunoPCR.  














Samples were all obtained from Kpone-on-Sea, a small fishing village on the 
southeastern coast of Ghana in 2002. The community has been developed as a model 
site for malaria intervention studies by the WHO-funded Kpone Malaria Project. Peak 
malarial transmission in this area occurs from May to July and in November with a peak 
parasite rate of 21% in children under five. At the time of collection the overall 
prevalence of malaria was about 11%, of which greater than 95% were P. falciparum.  
290 study subjects were recruited from symptomatic patients at the Kpone Health 
Center, of which 187 were adults, 58 were pregnant women, and 103 were children. 
Subjects were deemed inadmissible in the study if they had received a transfusion, had 
cerebral malaria, or had hemoglobin < 50 g/L.  
Information collected from participants included age and axillary temperature. Blood and 
urine samples were collected for each patient and transported to School of Public Health 
(SPH) and the Noguchi Memorial Institute for Medical Research (NMIMR), University of 
Ghana, Legon, for further processing. Blood samples were used to make thin-film slides 
(to determine parasite species), thick-film slides (for parasitemia), and for use on a rapid 
diagnostic test. 20-150 mL of fresh clean-catch urine was collected for each participant, 
and 202 urine samples were ultimately available for use. Aliquots of samples were sent 
to Johns Hopkins School of Public Health. Urine samples were adjusted to pH 7-9 and 
subjected to Biorad CBB protein (Hercules, CA) assay for protein concentration. Urine 
samples were also tested for presence of PfHRPII using Western and dot blots in 2005, 
as well as given the Binax buffered urine-specific (BUS RDT) malaria test using 100 
microliters of sample for each test). Samples were frozen and stored until the present 
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analysis in 2016. All plasma and blood samples were diluted 1:100 with sterile 1X PBS 
for ELISA analysis, and diluted by 1:10 for ImmunoPCR analysis.  
Binax buffered urine specific RDT 
In 2005 , Binax created a pilot prototype urine malaria test stick utilizing the same 
aldolase and HRP2 antibodies for the FDA approved Binax Now malaria blood RDT. The 
test had a large absorbant pad distal to the read zone, wick, conjugate pad and sample 
pad, Approximately 150 to 200 microL of urine was absorbed up the dipstick to be 
analyzed. The test has a 40 picogram limit of detection for recombinant HRP2. 
Western Blots 
Western Blots of samples were initially performed at Johns Hopkins School of Public 
Health. Those used for nanoparticle analysis were performed at George Mason 
University using slightly different materials; these are described below with other 
portions of the nanoparticle protocol.  
For initial analysis of samples, 10 microliters of each urine sample was mixed with 3.3 
microliters of 4x Sample Buffer (Bio-Rad) and boiled for 10 minutes 95°C. In subsequent 
blots, different quantities of sample were used to manipulate relative intensities for 
easier viewing. After boiling, samples were loaded into a 4–20% Mini-Protean TGX Gel 
(Bio-Rad) for Western Blotting for electrophoresis. After this, proteins were transferred to 
a nitrocellulose membrane for one hour at 0.400 Amps and 250 V in transfer buffer 
(made with 3.03 grams Tris-HCl, 14.4 g glycine, 200 mL methanol and 1 mL 10% SDS 
brought to 1 liter of solution with deionized water). The membrane was then placed in 40 
mL blocking solution (5% powdered milk, 2% bovine serum albumin in 0.1% PBS-
Tween, diluted by 1:5 with 0.1% PBS-Tween) for one hour at RT. 20 uL of 3A4 
monoclonal primary antibody was then added to 40 mL of 1:5 blocking solution. Blots 
were then incubated in this solution at RT for 90 minutes. After rinsing with 0.1% PBS-
Tween five times with five minutes in between each, the membranes were placed in 40 
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mL of 1:5 blocking solution with 20 uL of secondary goat antimouse IgG + IgM antibody. 
The membrane was exposed on Amersham Hyperfilm ECL (GE Healthcare, UK) using 
ECL Western Blot detection reagents (GE Healthcare, Buckinghamshire, UK), using 10 
minute exposures.  
Coomassie Brilliant Blue 
Coomassie Briliant Blue staining was performed on one gel of matched plasma-urine 
pairs to visually detect other proteins. The gel was run as described for Western Blots, 
then transferred to a large plastic petri dish and coated in approximately 40 mL of 
Coomassie Brilliant Blue solution (1g Coomassie Brilliant Blue stain, BioRad, in 1 liter of 
40% Methanol, 10% acetic acid, and 30% H2O). This was incubated overnight, then 
destained repeatedly in 15 minute intervals until the background became clear. 
Destaining solution was made of 50% H2O, 40% methanol, and 10% acetic acid.  
 
Dot Blots 
10 microliters of each sample was mixed with 90 microliters of 1x PBS in separate wells 
of a 96-well plate. Each of these was then transferred to a 0.45 mm nitrocellulose 
membrane (Bio-Rad) using a suction-based dot blot apparatus. The membrane was then 
subjected to the same blocking and antibody steps as membranes from a Western Blot, 
described above.  
 
Immuno PCR 
ImmunoPCR was performed by Dr. Kei Mikita in 2005, as described in his paper 
quantifying PfHRPII in cerebrospinal fluid59. All plasma samples were diluted 1:10, and 
all urine samples were used without dilution. Briefly, monoclonal antibody 3A4 was used 
as the capture antibody and incubated overnight at 4 degrees in 96 well microplates. 
After washing and blocking, 5 uLs of sample were diluted in 15 uL of blocking buffer and 
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incubated in wells overnight at RT. After a second set of washes, oligo-HRP2 antibody 
was added and incubated for 2 hours at RT. After washing the oligo-antibody, PCR-
grade water was added, followed by sealing the microplates and placing them in boiling 
water to denature the antigen-antibody-oligonucleotide product. Real-time PCR was then 
performed to quantify the presence of the oligonucleotide using forward primer (5’-GAC 
AGC GTA CGA CCA ACC T-3’), reverse primer (5’-GAC CTT GCT GCT GGT ATT TC-
3’), Texas red probe (5’-CCG GGT CTG ATC GGC GAT-3’) and 4.5 microliters iQTM 
Multiplex Powermix (Bio-Rad, USA). 
 
ELISA 
A CELISA kit for Malaria Antigen made by CelLabs in Australia was used according to kit 
instructions43. Both plasma and urine samples were diluted with sterile PBS based on 
preliminary dot blots and ELISAs to bring quantities into the approximate linear range of 
the test. Previous work in our lab yielded a much smaller range of linearity for the 
concentration of PfHRP2 than the literature (which found a range of 0.391 to 25 
nanograms per 100 uL test sample)42, ranging from 1 ng down to 0.05 in a 100 microliter 
aliquot. These concentrations were used as the standard curve for further ELISAs as 
well as preliminary dot blots. Dilutions ranged from 1:40 to no dilution, and duplicates of 
each sample were run. Diluted samples were incubated in the wells of the ELISA plate 
(pre-coated with monoclonal antibodies against PfHRPII) for one hour, then washed five 
times with wash buffer (PBS-Tween, from kit, diluted 1:20 as described). Subsequently, 
100 microliters of freshly diluted conjugate-antibody solution was added to each well for 
a second one-hour incubation at RT. Following another five washes, 100 microliters of 
freshly-diluted chromogen substrate was added to each well using a multichannel pipet. 
The plate was then wrapped in foil and put into a drawer to incubate for 15 minutes 
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before adding 50 microliters of stop solution. Plates were then read using a 
spectrophotometer (POLARStar Omega).  
For analysis, the background reading for negative controls was subtracted from the raw 
reading. Samples with a low “adjusted” reading (calculated by subtracting the reading 
from a negative well; readings below .02 were considered too low to quantify) were 
removed from analysis, leaving only 10 quantifiable ratios. For each sample, an average 
of the two wells was taken for computing the total readout; all samples were normalized 
to a reading and parasitemia for 1 mL of solution. Geomeans of urine and plasma 
protein concentrations, geomeans of ratios of concentrations (plasma to urine), as well 
as the ratio of the geomeans of plasma to urine concentration were computed.  
Nanoparticles 
Nanoparticles and all Western Blots and analysis pertaining to their use were generated 
at George Mason University in Manassas, Virginia under the guidance of Drs. Lance 
Liotta and Alessandra Luchini.  
Nanoparticles themselves were manufactured by other members of the lab. After testing 
with nanoparticle functionalized using different dyes, “Remazol Brilliant Blue” particles 
were selected (see Results) and manufactured as previously described 65.  
For preliminary determination of optimal nanoparticle and nanoparticle quantity, and as a 
control when running samples, urine spiked with recombinant HRPII protein was used. 
Fresh urine was captured and spun for 15 minutes at speed to remove excess proteins, 
then calibrated to pH 8.0. Specific quantities of recombinant PfHRPII protein was added 
prior to use in nanoparticle incubation process.  
To capture antigen with the nanoparticles, 500 microliters of spiked urine HRPII or 
patient urine samples were incubated with 150 microliters of nanoparticles at room 
temperature on a rotator for one hour, then spun at 16,100 rcf for 15 minutes. The 
supernatant from this spinning step was placed in a separate Eppendorf tube and saved 
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for analysis via Western Blot (to determine how much of the protein in question was . 
The nanoparticle pellet was then washed in 1 mL of water and fully resuspended, then 
spun again for 15 minutes at 16,100 rcf. The wash solution was removed and discarded, 
and the nanoparticle pellet was resuspended in 35 microliters of 2X Sample Buffer (Bio-
Rad) with a 1:20 dilution of TCEP and placed on a 95 degree heat block for 10 minutes. 
These were then centrifuged at 16,100 rcffor 25 minutes; the supernatant from this final 
spin was transferred to Eppendorf tubes labeled “eluate” and analyzed using Western 
Blots.  
Western Blot protocols undertaken at George Mason University differed slightly from 
those at Johns Hopkins School of Public Health. 4X sample buffer (Bio-Rad) with TCEP 
was used to denature proteins for 10 minutes at 100 degrees. For samples and 
supernatants, 15 microliters were combined with 5 microliters of loading buffer and 
boiled for 10 minutes at 100 degrees. For eluates from nanoparticle incubation, boiling 
was performed as described prior to the final centrifugation step, and yielded 
approximately 30 microliters of final solution. These samples were run on Novex 4-20% 
Tris-Glycine gels (Invitrogen) for 45 minutes at 200 mV using Tris-Glycine SDS running 
buffer in a Novex X-Cell IITM Mini-Cell (Invitrogen). Transferring was performed in the 
Novex Mini-Cell (Invitrogen) in transfer buffer (made with 3.03 grams Tris-HCl, 14.4 g 
glycine, 200 mL methanol and 1 mL 10% SDS brought to 1 liter of solution with 
deionized water) for 105 minutes at 25 mV onto PVDF membranes (Millipore) that were 
soaked for one minute in methanol prior to use. Membranes were then blocked in 10 mL 
of I-Block (Applied Biosciences) solution for one hour on a shaker; this was then 
discarded, and 10 mL 0.2% I-Block (Applied Biosciences) with 0.1% Tween 20 (Fisher) 
plus 10 uL of 3A4 antibody was added for 90 minutes on a shaker. Subsequently, blocks 
were subjected to 5, five-minute washes in 0.01% PBS-T before being placed in 10 mL 
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of I-Block with 3 mL of anti-mouse secondary antibody for an hour at room temperature 
on a shaker. After this final incubation period, blots were washed 5 more times in 0.01% 
PBS-T for 5 minutes each before imaging. Proteins were detected using 
chemiluminescence (SuperSignal West Dura, ThermoFischer Scientific) on a Kodak 
MM4000 Imager.  
Analysis 
All analysis was done in GraphPad Prism and Stata. Logistical regression analysis was 
used to determine the change in odds of positive results on various urine-based 
diagnostic tests (i.e. dot blot, western blot, ImmunoPCR, and ELISA) using criteria such 
as blood parasitemia, protein level in the urine, and presence or absence of fever. All 
analysis was undertaken using the assumption that thick-film microscopy continues to be 







A total of 202 urine samples were available for analysis. Of the patients from which this 
urine was procured, 16 had parasites/ul >= 100,000, 43 = pars/ul 5,000-99,999, 43 had 
mild malaria with less than 500-5,000/ul and 28 had less than 500/ul. 72 had no malaria 
on the blood film (Figure 2). A total of 29 urine samples contained traces of blood.  
Parasitemia was categorized for analysis into the four aforementioned categories (no 
parasitemia, 500 to 4,999 parasites/mL, 5000-99,999 parasites/mL, and >=100,000 
parasites/mL) for analysis. In total 27 persons were febrile with 7 in the nonparasitemic 
group. 
Table 1 shows counts of patient samples divided by microscopic parasitemia and other 
diagnostic criteria, with a subset divided by febrile status. Microscopy was considered 
the “gold standard” for malaria in all analyses, despite the fact that ImmunoPCR may be 
more sensitive.  
 
Western Blot analysis 
Samples positive by microscope as the “gold standard” for which we had 10 microL of 
urine were analyzed via Western Blot, along with negative controls. In total, 74 
microscopy-positive and 12 microscopy-negative samples were run, for a total of 86 
samples (Table 1). Figure 3 shows a representative sample Western Blot. Of the 74 
microscopy-positive, 19 were positive by Western Blot, yielding approximately a 25.7% 
sensitivity. 12 microscopy-negative urine samples were also run, all of which gave 
negative results, for a specificity of 100%. A total of 3 Western-positive samples 
contained traces of blood, while 10 Western-negative samples contained blood. 
Comparing the Western Blot of urine to the “gold standard” of microscopic parasitemia 
showed a 36.0% agreement.  
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Analyzing by febrile status, 6 of 17 (35.3%) microscopy-positive with fever were 
Western-positive, while only 13 of 67 (22.8%) of afebrile, microscopy-positive patients 
were Western-positive (Table 1).  
Regression analysis yielded a statistically significant relationship between odds of 
positive Western Blot results and proteinuria below 600, parasitemia (as a categorical 
variable), but a nonsignificant relationship with fever and proteinuria above 600, when 
taken individually. Each additional level of parasitemia was associated with 2.8 times the 
odds of a positive Western result (95% CI: 1.37 to 5.56, p<0.01) when taken alone. 
When controlling for proteinuria and fever, this relationship was attenuated and still 
statistically significant, with an odds ratio of 2.16 (95% CI 1.05-4.48, p<0.05) for each 
increase in parasitemia level. Proteinuria was only statistically significantly related to 
odds of positive Western results below 600 mcg/mL of protein, with a 0.1% increase in 
odds for each unit increase in protein content of the urine (95% CI 1.001-1.008, p=0.01). 
Fever was not statistically significantly correlated with odds of Western Blot positivity, but 
attenuated the relationship of categorical parasitemia level with Western Blot positivity.  
 
Dot blot analysis  
 
All 202 urine samples were analyzed by dot blot again with 10 microL of urine; the 
subset for which ELISA was performed also had plasma analyzed by dot blot. Figure 4 
shows a representative dot blot for urine, and figure 5 shows the dot blot for plasma. Dot 
blot analysis was more sensitive than Western Blot analysis, but less specific. Overall, 
51 of the 130 patients with microscopic-level parasitemia were positive by dot blot, 
implying a 39.2% sensitivity. Of the 21 febrile patients with malaria, 10 (or 48%) were 
Dot blot positive; for the 110 afebrile patients, 42 (38%) were Dot blot positive. Of those 
without microscopic malaria, 59 out of 72 did not have visible PfHRPII by Dot blot; this 
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implies a specificity of 80%, with 13 false positives. Ten samples that were dot blot 
positive contained traces of blood, while 19 samples that were dot blot negative 
contained traces of blood.  
Univariate logistic regression analysis yielded a statistically significant relationship 
between odds of positive dot blot and categorical parasitemia (OR = 1.33, 95% CI = 
1.07-1.67, p<0.05), and proteinuria below 600 (OR = 1.003, 95% CI 1.001-1.005, 
p=0.005), but no significant relationship existed for proteinuria above 600 or for fever. In 
multivariate analysis, categorical parasitemia no longer statistically significantly predicted 
dot blot positivity (OR = 1.18, CI = 0.93-1.51, p=0.17) when controlling for proteinuria 
and parasitemia.  
 
Buffered urine-specific (BUS) RDT 
Of the 130 microscopy-positive individuals whose urine was tested with the buffered 
urine-specific RDT, 42 had a positive result, yielding a 32.3% sensitivity. Of the 72 
microscopy-negative samples analyzed, 1 yielded a positive BUS RDT result, yielding a 
99% specificity. Overall, the BUS RDT had a 55.9% agreement with microscopy, higher 
than both Western blot and dot blot, making it the highest of the three urine-detection 
methods used. There was a 76.7% agreement with the Western Blot, with the BUS RDT 
as the more sensitive test (McNemar’s test, OR = 3, 95% CI=1.04-10.56, p<0.05). 
Comparing to the dot blot, the BUS RDT had a 70.8% agreement, but the BUS RDT was 
less sensitive (McNemar’s test, OR = 0.475, 95% CI 0.260-0.840, p<0.01).  
Among those with microscopic malaria and fever, the BUS RDT yielded a positive result 
in 60% of cases, whereas afebrile, microscopy-positive cases had positive BUS results 
in only 24% of cases.  
Univariate logistic regression analysis demonstrated a statistically significant relationship 
between odds of positive BUS RDT and categorical parasitemia (OR=2.86, 95%CI= 
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2.04-4.02, p<0.001), proteinuria below 600 (OR = 1.006 per unit increase in proteinuria, 
95% CI = 1.003-1.008, p=<0.001), and fever (OR=3.71, 95%CI = 1.58-8.71, p<0.01), but 
nonsignificant relationships with proteinuria above 600 (OR=0.998, 95%CI = 0.994-
1.002, p=0.40). 
Multivariate logistic regression analysis attenuated all these relationships, but they 
remained significant or bordering on significant. Each increase in microscopic parasite 
level was associated with a 2.56 times higher odds of BUS RDT positivity (95% CI 1.80-
3.72, p<0.001), and each unit (micrograms/mL) increase in proteinuria below 600 
micrograms/mL was associated with a 0.4% increase in odds of positive BUS RDT (95% 
CI 1.001-1.006, p<0.001). Having a fever was associated with 2.94 times the odds of 
positive BUS RDT, but this relationship was borderline nonsignificant when controlling 
for other variables (95% CI = 1.00-8.7, p=0.052).  
 
Aim 2:  
ELISA quantification of PfHRPII in urine and plasma samples 
A subset of microscopy-positive samples for which ImmunoPCR analysis had been 
performed and for which plasma and samples were available were selected for analysis. 
Preliminary ELISA analysis on some of these urine samples yielded undetectable 
amounts of urine PfHRPII; these samples were removed from consideration, as they 
would skew the ratio to make it appear higher. In the final ELISA, twenty matched pairs 
of plasma and urine were analyzed; 10 of these yielded detectable, quantifiable PfHRPII 
concentrations in urine (the limiting factor, as it had lower concentratins) and thus 
yielded calculable ratios. Of these final 10, 2 were febrile and 8 were afebrile (Table 1).  
Figure 6 shows the concentrations of PfHRPII in the matched urine and plasma samples 
as determined by ELISA, along with descriptive statistics. The geometric mean of the 
concentration of PfHRPII in plasma was 1732.0 (95% CI: 743.1-4036.9) while that of 
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PfHRPII in urine was 25.1 ng/mL (95% CI: 4.8 to 130.8). This data is statistically 
significantly different, with a median difference of -1522 ng/mL between plasma 
concentration of PfHRPII and urine concentration of PfHRPII (Wilcoxon paired t-test, 
p=0.002). The geometric mean of the ratios was 69.0 (95% CI: 16.8-282.6), which was 
the same as the ratio of geometric means.  
  
ImmunoPCR quantification of PfHRPII in urine and plasma samples 
70 matched plasma and urine samples had previously been analyzed by ImmunoPCR 
for quantity of PfHRPII. Of these, 36 had microscopy-confirmed malaria (with 4 febrile 
patients), while 34 did not (with 2 febrile patients; see Table 1). ImmunoPCR results 
were dichotomized into “positive” and “negative” with a cutoff of 1 ng/mL as the minimum 
quantity of PfHRPII detection necessary for a “positive” result (see Table 1). Figure 7 
shows concentrations of PfHRPII in the matched urine and plasma samples of 
microscopy-positive patients; including microscopy-negative patients would 
unnecessarily skew the data. There was a statistically significant difference in PfHRPII 
concentration between the two body fluids, with an average difference of -21360 ng/mL 
between plasma and urine (Paired t-test, 95% CI: -35660 to -7055, p<0.05). The 
geometric mean concentration in plasma was 1439.06 ng/mL, while that in the urine was 
10.5 ng/mL. The geometric mean of the ratio was 137.6 (95% CI: 54.2, 349.0; Table 2), 
while the ratio of the geometric means was 137.1. 
When ImmunoPCR was dichotomized into “positive” or “negative” for urine detection 
(with a threshold of 1 ng/mL), 24 were positive among 36 with microscopic malaria, 
implying a sensitivity of 66.7% (Table 1). Univariate logistic analysis yielded a 
statistically significant relationship between odds of ImmunoPCR detection and 
categorical parasitemia (OR=2.20, 95% CI= 1.36-3.5, p<0.01), proteinuria below 600 
(OR=1.009, 95%CI = 1.004-1.01, p<0.01), proteinuria above 600 (OR=0.99, 95%CI = 
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0.989-0.999, p<0.05), but not fever (OR=1.13, 95%CI=0.21-6.04, p>0.5). Multivariate 
logistic analysis maintained a statistically significant relationship between categorical 
parasitemia and odds of ImmunoPCR detection (OR=1.79, 95%CI=1.06-3.01, p<0.05) 
and proteinuria below 600 (with a .7% increase in odds per unit of proteinuria, 95% CI 
=0.2-1.3, p<0.01) but no relationship with proteinuria above 600 or fever. 
Analysis was then subdivided into those with malaria by microscopy (deemed the gold 
standard for this analysis) and those without. Table 2 shows PfHRPII ratios for those 
with and without malaria. Among those with microscopic malaria, the ratio of PfHRPII in 
plasma versus urine had a geometric mean of 134.3 (95% CI: 54.3-332.4). For the four 
febrile patients, the geometric mean ratio was 80.6 (95% CI: 1.6-4007.2), while for the 
32 afebrile patients the geometric mean ratio was 147.1 (95%CI: 53.3 to 405.8). The 
small sample size and large variation prevented this difference from achieving statistical 
significance.  
Comparison of ratios determined by ELISA and ImmunoPCR over all microscopy-
positive analyzed samples showed no statistically significant difference (Figure 8). 
Subsequent analysis was done on the subset of samples for which both ELISA and 
ImmunoPCR data was collected (Figure 9); this consisted of 9 samples, all of which 
were microscopy-positive for malaria. The mean geometric ratio of PfHRPII 
concentration as determined by ImmunoPCR was 26.7 (95% CI: 4.47-159.8), while that 
determined by ELISA was 55.9 (95% CI: 12.3 to 254.0); there was no statistically 
significant difference between the two. 
Figure 10 shows a Western Blot and Coomassie Brilliant Blue stain of matched urine-
plasma pairs. Equal volumes of urine and plasma were used within the pair set, and the 
rough equivalence of intensity in bands shows a rough 1:100 dilution factor of protein 





Nanoparticle selection and optimization 
Figure 11 shows initial steps in choosing the appropriate nanoparticle for PfHRPII 
concentration using 500 microliters of samples (in this case, urine from healthy 
volunteers spiked with recombinant PfHRPII). Higher protein content in the eluate (i.e. 
protein captured in the nanoparticle) as well as low protein content in the supernatant 
(i.e. protein left behind in solution and not trapped by the nanoparticle) led to the 
selection of nanoparticle D, or Remazol Brililant Blue nanoparticles.  
Figure 12 shows a dilution curve of five-fold dilutions using malaria-negative urine spiked 
with recombinant PfHRPII. ImageJ analysis yielded a six-fold change in band intensity 
(i.e. protein content) between the initial sample and the eluate. The limit of detection was 
approximately 0.57 ng/mL, with a theoretical total of 0.285 nanograms in 500 microliters 
(Figure 12). 
In total, nine samples were tested with the nanoparticles; six of these had previously 
yielded positive results on a Western Blot, and three were microscopic parasitemia-
negative controls. Figure 13 shows an example Western Blot run with samples. PfHRPII 
was only detected in the eluate of one sample, Sample 7 (see Figure 13). All other 











Figure 2. Distribution of microscopic parasitemias of Ghanaian patient samples. All 


















Microscopy - Microscopy + Microscopy - 
   Febrile Afebrile Febrile Afebrile 
Total (n=202) 131 71 20 110 7 65 
Western (n=86)       
Western + 19 0 6 13 0 0 
Western - 55 12 11 44 0 12 
Dot blot (n=202)       
Dot blot + 51** 13** 9 42 3 10 
Dot blot - 79** 59** 11 68 4 55 
IPCR (n=70)       
IPCR + 24** 9** 3 21 0 9 
IPCR -  12** 25** 1 11 2 23 
ELISA (n=10)       
ELISA + 10 0 2 8 0 0 
ELISA - 0 0 0 0 0 0 
BUS (n=202)       
BUS RDT + 42** 1** 12** 30** 0 1 
BUS RDT - 88** 71** 8** 80** 7 64 
 
Table 1. Sample counts and positive results for various diagnostic techniques 
detecting PfHRPII in urine. ImmunoPCR (IPCR) positive was deemed as having any 
reading over 1 ng/mL. BUS denotes buffered urine-specific test, manufactured by Binax. 
“Gold standard” was considered to be blood smear microscopy. Fisher’s exact test (two-
tailed) was used to compute statistical differences in group sizes comparing proportion 
of positive results on all listed urine-based detection methods comparing microscopy + to 
microscopy -, or febrile versus afebrile within microscopy categories. * denotes p<0.05, 







Figure 3. Representative Western Blot for detection of PfHRPII in 10 microliters of 
Ghanaian urine samples. (+) lanes indicate positive controls using recombinant 







Figure 4. Representative dot blot for detection of PfHRPII in 10 microliters of 
Ghanaian urine samples. First three spots represent a standard curve, while the rest 






Figure 5. Representative dot blot for detection of PfHRPII in 10 microliters each of 
Ghanaian plasma and urine samples. First six spots represent a standard curve, while 
last four are urine samples for comparison with other blots. All plasma samples are 

























Figure 6. Comparison of paired plasma and urine samples from microscopy-
positive Ghanaian patients (n=10) detecting PfHRPII using ELISA. Analysis shows a 
statistically significant difference in PfHRPII concentrations between the two fluids and a 
geometric mean ratio of plasma:urine of 68.97. Graph also displays 95% confidence 
intervals of geometric mean. Patients were all positive by microscopy (the gold standard 








Max: 10240.00 2053.40 714.93 
Min: 253.00 0.67 4.61 
Ave: 3073.35 249.98 224.66 
Median: 1507.00 15.14 155.05 
Geomean: 1732.00 25.11 68.97 

























Figure 7. Comparison of paired plasma and urine samples from microscopy-
positive Ghanaian patients (n=36) detecting PfHRPII using ImmunoPCR 
techniques. Analysis shows a statistically significant difference (Paired t test, p<0.01) in 
PfHRPII concentrations between the two fluids and a geometric mean ratio of 









Max: 158711 5490.40  54690.41 
Min: 2.98 0.08 1.22 
Ave: 22306.43 437.19 .2942.32 
Median: 2592.39 6.30 62.58 
Geomean: 1439.06 10.5 137.57 













Microscopy + Microscopy - 

















































       




























































































Table 2. Comparison of total urine protein content, urine PfHRPII content, 







Figure 8. Comparison of ratios of plasma-to-urine concentration of PfHRPII as 
measured by ImmunoPCR (n=36) or ELISA (n=10). Whiskers represent 95% 







Figure 9. Comparison of plasma-to-urine PfHRPII ratios determined by 
ImmunoPCR and ELISA for samples analyzed by both techniques (n=9). Whiskers 











Figure 10: Visual comparison of 1:100 dilution of plasma (P) to full samples of 
urine (U) in matched samples from Ghanaian patients using Western Blot (a) and 
Coomassie Brilliant Blue (b). Band intensities are roughly equivalent between pairs, 
implying a roughly 100-fold dilution in PfHRPII concentration in urine versus plasma. 
Western Blot(a) and CBB stain(b) of matched pairs of plasma (P) and urine (U) from P. 
falciparum-infected patients in Ghana. All plasma samples were diluted 1:100 prior to 
use. Lanes for samples 53, 20, and 63 contain 24 uL of sample, while lanes for sample 






Figure 11. Nanoparticle selection. Nanoparticle D is most efficient at concentrating 
PfHRPII from malaria-negative urine samples spiked with recombinant PfHRPII. PfHRPII 
was spiked in 500 µL of human urine from healthy volunteers (S) and incubated with 
Nanotrap particles functionalized with different dyes. After particle processing, PfHRPII 
in an optimal Nanoparticle should be depleted from the supernatant (SN) and easily 
detected in the eluate (E) to show nanoparticle capture. Lane 1 is a molecular weight 
ladder; Lane 2 is a positive control; Lane 3 shows 15 microliters of the original diluted 
sample, Lanes 4-5 are eluate and supernatant for Nanoparticle A, Lanes 6-7 are eluate 
and supernatant for Nanoparticle B, Lanes 8-9 are eluate and supernatant for 
nanoparticle C, and Lanes 10-11 are eluate and supernatant for Nanoparticle D. 
Nanoparticle D (Remazol Brilliant Blue) shows highest concentration of captured 










Figure 12. Dilution curve using nanoparticle concentration to determine limit of 
detection using 500 microliter samples. The limit of detection for nanoparticle-
concentration of 500 microliters of urine spiked with recombinant PfHRPII is 0.57 ng/mL 
(285 ng in sample). Different quantities of recombinant PfHRPII were spiked into the 
urine of healthy volunteers and diluted sequentially 1:5. Lanes marked “S” contain 15 
microliters of original diluted samples corresponding to the concentration listed below the 
blot. Lanes marked E contain eluate from 500 microliters of sample at the concentration 
listed below incubated with Remazol Brilliant Blue nanoparticles. Lanes marked “SN” 
contain 15 microliters of left over supernatant from nanoparticle protocol corresponding 
to sample with concentration listed below to show protein not captured in the 




Figure 13. Testing of nanoparticles for concentration of PfHRPII in clinical 
samples. Incubation of Ghanaian urine samples with Nanotrap particles was suboptimal 
for all but one sample. Western Blot performed for detection of PfHRPII, with a 
recombinant control in lanes 2-4 and patient samples in lanes 5-12. (S) denotes original 
sample, (E) denotes eluate (i.e. PfHRPII protein captured inside nanoparticle), and (SN) 
denotes supernatant (i.e. PfHRPII protein not captured inside nanoparticle). Of all 10 







This work demonstrates some of the challenges present in creation of urinary malaria 
diagnostics. Both the dot blot and Western Blot themselves had low sensitivity with 10 
microL analyzed, with the dot blot suffering additionally from hampered specificity. 
Although ImmunoPCR also had imperfect specificity, this could in theory be an artifact of 
increased sensitivity. However, it also had a 66% sensitivity as compared to microscopy 
and thus would miss some cases if used as the “gold standard”. The buffered urine-
specific test used about 50 to 70 microL and was more sensitive than the Western Blot 
but less sensitive than the dot blot, although it was 99% specific versus 80% specific. 
The BUS-RDT had higher sensitivity among those with fever and malaria, correctly 
identifying 60% of malaria cases in febrile malaria patients versus 37.5% in afebrile 
patients.  
Among all microscopy-positive samples tested, the quantity of PfHRPII has a 
geometric mean of 25.11 ng/mL and a median of 15.1 ng/mL by ELISA (Figure 6); with a 
geometric mean of 10.5 ng/mL and a median of 6.30 ng/mL by ImmunoPCR (Figure 7);, 
The lower immunoPCR number  is from inclusion of many more low PfHRPII samples in 
immunoPCR near the level of detection by immunoPCR, not detected by ELISA. 
Considering all 70 samples (microscopy positive and negative), ImmunoPCR yields a 
geometric mean plasma to urine ratio of 57.1; however, this is likely to be skewed by 
negative points. When including malaria-negative samples, ImmunoPCR yields a much 
lower mean and median; this discrepancy is due to the inclusion of presumably negative 
samples in the overall analysis, so analysis was primarily done on malaria-positive 
patients. ELISA shows an approximate geometric mean plasma to urine ratio of 69. 
However, none of these appear to be statistically significantly different. Figure 10 
demonstrates visually that the quantity of PfHRPII in 100-fold dilution of plasma is 
 
 44 
approximately equal to that of its undiluted matched urine sample. Taken all together, we 
can round to an approximate 100-fold higher concentration of PfHRPII in plasma as 
compared to urine by these ratios. 
 In addition, as mentioned, the geometric mean quantity of PfHRPII in urine was 
25 ng/mL using an ELISA technique and 10.5 ng/mL using ImmunoPCR (Figures 6 and 
7); to reach the approximate functional limit of detection of 200 ng/mL, this would require 
10-100 times more sample volume or a test with 10-100 times greater sensitivity. 
However, there still exists an enormous amount of variability in the quantities of PfHRPII 
detected as seen in the very wide ranges (Figures 6 and 7, Table 2). This implies that 
basing our needs on the geomean may still yield inadequate overall sensitivity.  With an 
100-fold increase, 15/36 (or 40.5%) of microscopy-positive samples are still below the 
200 ng/mL threshold using quantities detected by ImmunoPCR, yielding a sensitivity of 
59.5%. With a 200-fold increase, 12/36 (33.3%) will be difficult to detect, and even at a 
500-fold increase 5/37 (13.8%) will remain below the assumed 200 ng/mL limit of 
detection, with roughly 87.5% sensitivity. Among those analyzed by ImmunoPCR and 
microscopy-positive for malaria, the minimum value of PfHRPII concentration is 0.08 
ng/mL. By this metric, in order to detect all samples at 200 ng/mL, we would need a 
2500-fold increase in sample volume. Given that most blood-based RDTs use 10 
microliters of blood, this would entail a 25 mL sample.  
Based on our analysis of the capabilities of Nanotrap technology using 500 
microliters of sample, the nanoparticles are still inadequate to overcome this barrier of 
dilution, as only one patient sample was successfully concentrated (Figure 13). Greater 
sample quantities (as used in the Lyme test, for instance) may help overcome this 
apparent failure; as discussed above, a much larger increase in sample size (at least 
2500-fold) would be necessary to mitigate the decreased concentration of PfHRPII in 
urine. Even so, proteins that were successfully captured and concentrated from 500 
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microliters in Nanotrap technology showed only a 6-fold increase in band intensity for 
PfHRPII as compared to identical 15 microliter samples run without Nanotrap (Figure 
12), which is much less than the 31-fold increase in sample quantity, implying an 
imperfect capture of antigen. This could potentially be rectified through changes to the 
specific dye used as bait within the nanoparticle, as higher affinity dyes are continuing to 
be discovered.  
 This around-100-fold ratio is also much lower than that typically observed of 
normal proteins in normal patients. For normal patients without fever, blood protein 
levels are typically 400 times urine protein levels. This is likely due to an overall increase 
in protein shedding. Infection with malaria67 and fever68 have both independently been 
found to be associated with proteinuria in the past. One study found that 78% of malaria 
cases observed experienced transient proteinuria, even in the absence of overt renal 
failure69. Among malaria-infected patients, fever appears to be associated with greater 
proteinuria67, and level of proteinuria may be correlated (albeit not statistically 
significantly) with parasitemia70. We also found that the ratio of PfHRPII concentration in 
plasma to that in urine was only 80 for febrile patients, versus 147 in afebrile patients 
(Table 2), again implying a role of fever in aiding detection (although due to small 
sample size, the difference was not statistically significant).  
 This would imply that in our study, febrile patients would be more easily 
diagnosed. 28% of febrile patients with microscopic malaria were positive by Western, 
versus 11% of afebrile patients (Table 1). 60% of malaria-infected, febrile patients were 
positive by buffered urine-specific RDT, whereas only 37% of afebrile patients had 
detectable levels of PfHRPII. Fever was also associated, nonsignificantly with increased 
odds of positive results on all tested diagnostic mechanisms in univariate analysis, and a 
statistically significant relationship with odds of positive BUS-RDT result. However, the 
relationship did not maintain statistical significance when controlling for protein content 
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and parasitemia, and there is no correlation between fever and overall protein content 
itself in this data. Regardless, there is an important trend towards higher odds of protein 
detection in febrile patients. Though this can be seen as a possible problem in terms of 
finding all potential reservoirs of parasites, a diagnostic that is only reliable when used 
on febrile patients will still help prevent incorrect prescription of antimalarials to febrile 
patients presenting at local health centers. There was also an interesting trend in the 
odds of positive results on all tests, which increased significantly (by two fold or more) 
with each increase in categorical parasitemia level. This also adds to the possibility that 
any urine-based test would be most useful only on symptomatic patients with high 
parasitemia, and implies that urinary PfHRPII may be a strong indicator of overall 
parasitemia as well.  
 Analysis was also performed to discern whether this 100-fold dilution was likely 
to be the same for all proteins, or if there was PfHRPII-specific concentration manifesting 
itself. Given that normal plasma contains about 80 mg/mL of protein, and the geometric 
mean concentration of PfHRPII in plasma was approximately 1500 ng/mL by 
ImmunoPCR for microscopy-positive patients, so PfHRPII is about 1/53,333 in plasma. 
In the urine, total protein content had a geomean of 122 micrograms/mL in microscopy-
positive patients, while PfHRPII content was about 10.5 ng/mL. Thus, in urine, PfHRPII 
is about 1/12,000 of the protein content. This may be due to its relatively hardy nature, 
such that other blood proteins degrade.  
 Another issue with urine-based diagnostics are the presence of blood in urine, 
and whether that is a factor for being able to detect PfHRPII. There was otherwise no 
pattern of increased proportion of patients with bloody urine who received positive or 
negative diagnoses, implying that this is unlikely to be the only explanation for being able 
to detect PfHRPII in urine.  
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 In summary, although PfHRPII is detectable in urine via multiple techniques and 
may be particularly promising as a biomarker in symptomatic patients, technology will 
require at least a 100 fold increase in sensitivity or testable sample volume  to make 
urinary diagnosis of malaria a viable option. Future analyses could include continued 
exploration of the nanoparticle technology using greater volumes of urine and potentially 
testing for higher-affinity particles, as well as continuing to explore other correlates of 








1.  WHO. Malaria fact sheet. http://www.who.int/mediacentre/factsheets/fs094/en/. 
Accessed August 29, 2016. 
2.  Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of 
clinical episodes of Plasmodium falciparum. Nature. 2005;434(3):214. 
doi:10.1029/2002gb001991. 
3.  CDC. Elimination of malaria in the United States (1947-1951). 
http://www.cdc.gov/malaria/about/history/elimination_us.html. Accessed August 
29, 2016. 
4.  Cullen KA, Arguin PM. Malaria surveillance--United States, 2012. MMWR Surveill 
Summ. 2014;63(12):1-22. doi:10.1016/S0887-7963(98)80014-X. 
5.  Hay S, Guerra C, Tatem A, Noor A, Snow R. The global distribution and 
population at risk of malaria: past, present, and future. Lancet Infect Dis. 
2004;4(June). doi:10.1016/S1473-3099(04)01043-6. 
6.  MALWEST. Plasmodium life cycle. http://www.malwest.gr/en-
us/malaria/informationforhealthcareprofessionals/plasmodiumlifecycle.aspx. 
Accessed August 29, 2016. 
7.  CDC. CDC - Malaria - About Malaria - Biology - Malaria Parasites. USA 
Government. http://www.cdc.gov/malaria/about/biology/parasites.html. Published 
2012. 
8.  Bhattarai A, Ali AS, Kachur SP, et al. Impact of artemisinin-based combination 
therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med. 
2007;4(11):1784-1790. doi:10.1371/journal.pmed.0040309. 
9.  CDC. Insecticide-treated Bed Nets. Malaria. 
10.  Rehman AM, Coleman M, Schwabe C, et al. How much does malaria vector 
control quality matter: The epidemiological impact of holed nets and inadequate 
 
 49 
indoor residual spraying. PLoS One. 2011;6(4). 
doi:10.1371/journal.pone.0019205. 
11.  Bhatt S, Weiss DJ, Cameron E, et al. The effect of malaria control on Plasmodium 
falciparum in Africa between 2000 and 2015. Nature. 2015;526(7572):207-211. 
doi:10.1038/nature15535. 
12.  Kleinschmeidt I, Schwabe C, Shiva M, et al. Combining indoor residual spraying 
and insecticide-treated nets interventions. Am J Trop Med Hyg. 2009;81(3):519-
524. 
13.  Hsiang MS, Hwang J, Tao AR, et al. Mass drug administration for the control and 
elimination of Plasmodium vivax malaria: an ecological study from Jiangsu 
province, China. Malar J. 2013;12(1):1-14. doi:10.1186/1475-2875-12-383. 
14.  WHO Evidence Review Group. Mass drug administration, mass screening and 
treatment and focal screening and treatment for malaria. 2015;(September):1-27. 
http://www.who.int/malaria/mpac/mpac-sept2015-erg-mda-report.pdf. 
15.  Newby G, Hwang J, Koita K, et al. Review of mass drug administration for malaria 
and its operational challenges. Am J Trop Med Hyg. 2015;93(1):125-134. 
doi:10.4269/ajtmh.14-0254. 
16.  Griffin JT, Hollingsworth TD, Okell LC, et al. Reducing Plasmodium falciparum 
malaria transmission in Africa: A model-based evaluation of intervention 
strategies. PLoS Med. 2010;7(8). doi:10.1371/journal.pmed.1000324. 
17.  Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria 
chemoprophylactic regimens in tourists visiting East Africa. Lancet. 
1993;341(8856):1299-1303. doi:10.1016/0140-6736(93)90814-W. 
18.  Ferri F. Malaria. In: Ferri’s Color Atlas and Text of Clinical Medicine. Elsevier Inc.; 
:1159. 
19.  MacKintosh CL, Beeson JG, Marsh K. Clinical features and pathogenesis of 
 
 50 
severe malaria. Trends Parasitol. 2004;20(12):597-603. 
doi:10.1016/j.pt.2004.09.006. 
20.  English M, Punt J, Mwangi I, McHugh K, Marsh K. Clinical overlap between 
malaria and severe pneumonia in African children in hospital. Trans R Soc Trop 
Med Hyg. 1996;90(6):658-662. doi:10.1016/S0035-9203(96)90423-X. 
21.  Ukwaja KN, Aina OB, Talabi AA. Clinical overlap between malaria and 
pneumonia: Can malaria rapid diagnostic test play a role? J Infect Dev Ctries. 
2011;5(3):199-203. doi:10.3855/jidc.945. 
22.  Sherman IW, Eda S, Winograd E. Cytoadherence and sequestration in 
Plasmodium falciparum: Defining the ties that bind. Microbes Infect. 
2003;5(10):897-909. doi:10.1016/S1286-4579(03)00162-X. 
23.  Idro R, Marsh K, John CC, Newton CRJ. Europe PMC Funders Group Cerebral 
Malaria ; Mechanisms Of Brain Injury And Strategies For Improved Neuro-
Cognitive Outcome. 2011;68(4):267-274. 
doi:10.1203/PDR.0b013e3181eee738.Cerebral. 
24.  UNICEF. Fact sheet: Malaria, a global crisis. 
http://www.unicef.org/media/media_20475.html. 
25.  Watsierah CA, Ouma C. Access to artemisinin-based combination therapy (ACT) 
and quinine in malaria holoendemic regions of western Kenya. Malar J. 
2014;13:290. doi:10.1186/1475-2875-13-290. 
26.  Wiseman V, Kim M, Mutabingwa TK, Whitty CJM. Cost-effectiveness study of 
three antimalarial drug combinations in Tanzania. PLoS Med. 2006;3(10):1844-
1850. doi:10.1371/journal.pmed.0030373. 
27.  Luxemburger C, Nosten F, Kyle DE, Kiricharoen L, Chongsuphajaisiddhi T, White 
NJ. Clinical features cannot predict a diagnosis of malaria or differentiate the 
infecting species in children living in an area of low transmission. Trans R Soc 
 
 51 
Trop Med Hyg. 1998;92(1):45-49. doi:10.1016/S0035-9203(98)90950-6. 
28.  Mazigo HD, Meza W, Ambrose EE, Kidenya BR, Kweka EJ. Confirmed malaria 
cases among children under five with fever and history of fever in rural western 
Tanzania. BMC Res Notes. 2011;4:359. doi:10.1186/1756-0500-4-359. 
29.  Mbonye AK, Lal S, Cundill B, Hansen KS, Clarke S, Magnussen P. Treatment of 
fevers prior to introducing rapid diagnostic tests for malaria in registered drug 
shops in Uganda. Malar J. 2013;12(1):131. doi:10.1186/1475-2875-12-131. 
30.  Cohen J, Dupas P, Schaner S. Price subsidies, diagnostic tests, and targeting of 
malaria treatment: Evidence from a randomized controlled trial. Am Econ Rev. 
2015;105(2):609-645. doi:10.1257/aer.20130267. 
31.  Arrow KJ, Panosian C, Gelband H. Saving Lives, Buying Time: Economics of 
Malaria Drugs in an Age of Resistance.; 2004. doi:ISBN-10: 0-309-09218-3. 
32.  UNICEF. Malaria mortality among children under five is concentrated in sub-
Saharan Africa. http://data.unicef.org/child-
health/malaria.html#sthash.mjlk11Ir.dpuf. Published 2016. Accessed August 29, 
2016. 
33.  Moody A. Rapid diagnostic tests for malaria parasites. Clin Microbiol Rev. 
2002;15(1):66-78. doi:10.1128/CMR.15.1.66-78.2002. 
34.  Milne LM, Kyi MS, Chiodini PL, Warhurst DC. Accuracy of routine laboratory 
diagnosis of malaria in the United Kingdom. J Clin Pathol. 1994;47(8):740-742. 
doi:10.1136/jcp.47.8.740. 
35.  Harchut K, Standley C, Dobson A, et al. Over-diagnosis of malaria by microscopy 
in the Kilombero Valley, Southern Tanzania: an evaluation of the utility and cost-
effectiveness of rapid diagnostic tests. Malar J. 2013;12(1):159. 
doi:10.1186/1475-2875-12-159. 
36.  Coleman RE, Maneechai N, Rachaphaew N, et al. Comparison of field and expert 
 
 52 
laboratory microscopy for active surveillance for asymptomatic Plasmodium 
falciparum and Plasmodium vivax in Western Thailand. Am J Trop Med Hyg. 
2002;67(2 SUPPL.):141-144. 
37.  WHO. Malaria Rapid Diagnostic Test Performance. 2011;3. 
38.  Miller E, Sikes HD. Diagnostic Tests in Global Health. 2015. 
doi:10.5772/61114.Addressing. 
39.  Bousema T, Okell L, Felger I, Drakeley C. Asymptomatic malaria infections: 
detectability, transmissibility and public health relevance. Nat Rev Microbiol. 
2014;12(12):833-840. doi:10.1038/nrmicro3364. 
40.  Murphy SC, Prentice JL, Williamson K, et al. Real-time quantitative reverse 
transcription PCR for monitoring of blood-stage Plasmodium falciparum infections 
in malaria human challenge trials. Am J Trop Med Hyg. 2012;86(3):383-394. 
doi:10.4269/ajtmh.2012.10-0658. 
41.  Slater HC, Ross A, Ouedraogo AL, et al. Assessing the impact of next-generation 
rapid diagnostic tests on Plasmodium falciparum malaria elimination strategies. 
Nature. 2015;528(7580):S94-S101. http://dx.doi.org/10.1038/nature16040. 
42.  Kifude CM, Rajasekariah HG, Sullivan DJ, et al. Enzyme-linked immunosorbent 
assay for detection of Plasmodium falciparum histidine-rich protein 2 in blood, 
plasma, and serum. Clin Vaccine Immunol. 2008;15(6):1012-1018. 
doi:10.1128/CVI.00385-07. 
43.  Cellabs. Malaria antigen CELISA. 
44.  Mayor A, Moro L, Aguilar R, et al. How hidden can malaria be in pregnant 
women? diagnosis by microscopy, placental histology, polymerase chain reaction 
and detection of histidine-rich protein 2 in plasma. Clin Infect Dis. 
2012;54(11):1561-1568. doi:10.1093/cid/cis236. 
45.  Noedl H, Yingyuen K, Laoboonchai A, Fukuda M, Sirichaisinthop J, Miller RS. 
 
 53 
Sensitivity and specificity of an antigen detection ELISA for malaria diagnosis. Am 
J Trop Med Hyg. 2006;75(6):1205-1208. 
46.  Bashir IM, Otsyula N, Awinda G, Spring M, Schneider P, Waitumbi JN. 
Comparison of PfHRP-2/pLDH ELISA, qPCR and Microscopy for the Detection of 
Plasmodium Events and Prediction of Sick Visits during a Malaria Vaccine Study. 
PLoS One. 2013;8(3). doi:10.1371/journal.pone.0056828. 
47.  Diggle E, Asgary R, Gore-Langton G, et al. Perceptions of malaria and 
acceptance of rapid diagnostic tests and related treatment practises among 
community members and health care providers in Greater Garissa, North Eastern 
Province, Kenya. Malar J. 2014;13:1-12. doi:10.1186/1475-2875-13-502. 
48.  Rodriguez-del Valle M, Quakyi IA, Amuesi J, Quaye JT, Nkrumah FK, Taylor DW. 
Detection of antigens and antibodies in the urine of humans with Plasmodium 
falciparum malaria. J Clin Microbiol. 1991;29(6):1236-1242. 
49.  Genton B, Paget S, Beck H, Gibson N, Alpers M, Hii J. Diagnosis of Plasmodium 
falciparum infection using ParaSight(R)-F test in blood and urine of Papua New 
Guinean children. Southeast Asian J Trop Med Public Heal. 1998;29(1):35-40. 
50.  Wyngaarden JB, Smith Jr. LH, Bennett JC. Cecil Textbook of Medicine. 19th ed. 
Philadelphia, PA: W. B. Saunders; 1992. 
51.  Oguonu T, Shu E, Ezeonwu BU, et al. The performance evaluation of a urine 
malaria test (UMT) kit for the diagnosis of malaria in individuals with fever in 
south-east Nigeria: cross-sectional analytical study. Malar J. 2014;13:403. 
doi:10.1186/1475-2875-13-403. 
52.  WHO. Selecting and procuring RDTs for malaria. 
http://www.who.int/malaria/areas/diagnosis/rapid-diagnostic-tests/selection-
procurement/en. Published 2015. Accessed August 29, 2016. 
53.  Howard RJ, Uni S, Aikawa M, et al. Secretion of a malarial histidine-rich protein 
 
 54 
(Pf HRP II) from Plasmodium falciparum-infected erythrocytes. J Cell Biol. 
1986;103(4):1269-1277. doi:10.1083/jcb.103.4.1269. 
54.  Desakorn V, Dondorp AM, Silamut K, et al. Stage-dependent production and 
release of histidine-rich protein 2 by Plasmodium falciparum. Trans R Soc Trop 
Med Hyg. 2005;99(7):517-524. doi:10.1016/j.trstmh.2004.11.014. 
55.  Dondorp AM, Desakorn V, Pongtavornpinyo W, et al. Estimation of the total 
parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med. 
2005;2(8):0788-0797. doi:10.1371/journal.pmed.0020204. 
56.  Iqbal J, Siddique A, Jameel M, Hira PR. Persistent histidine-rich protein 2, 
parasite lactate dehydrogenase, and panmalarial antigen reactivity after clearance 
of Plasmodium falciparum monoinfection. J Clin Microbiol. 2004;42(9):4237-4241. 
doi:10.1128/JCM.42.9.4237-4241.2004. 
57.  Pava Z, Echeverry DF, Díaz G, Murillo C. Short report: Large variation in 
detection of histidine-rich protein 2 in Plasmodium falciparum isolates from 
Colombia. Am J Trop Med Hyg. 2010;83(4):834-837. doi:10.4269/ajtmh.2010.10-
0075. 
58.  Rubach MP, Mukemba J, Florence S, et al. Plasma Plasmodium falciparum 
histidine-rich protein-2 concentrations are associated with malaria severity and 
mortality in Tanzanian children. PLoS One. 2012;7(5):3-7. 
doi:10.1371/journal.pone.0035985. 
59.  Mikita K, Thakur K, Anstey NM, et al. Quantification of Plasmodium falciparum 
Histidine-rich protein-2 in cerebrospinal spinal fluid from cerebral malaria patients. 
Am J Trop Med Hyg. 2014;91(3):486-492. doi:10.4269/ajtmh.14-0210. 
60.  Luchini A, Geho DH, Bishops B, et al. Smart hydrogel particles: Biomarker 
harvesting: One-step affinity purification, size exclusion, and protection against 
degradation. Nano Lett. 2008;8(1):350-361. doi:10.1021/nl072174l. 
 
 55 
61.  Tamburro D, Fredolini C, Espina V, et al. Multifunctional core-shell nanoparticles: 
Discovery of previously invisible biomarkers. J Am Chem Soc. 
2011;133(47):19178-19188. doi:10.1021/ja207515j. 
62.  Luchini A, Espina V, Liotta L a. Protein painting reveals solvent-excluded drug 
targets hidden within native protein-protein interfaces. Nat Commun. 2014;5:4413. 
doi:10.1038/ncomms5413. 
63.  Fredolini C, Tamburro D, Gambara G, et al. Nanoparticle technology: Amplifying 
the effective sensitivity of biomarker detection to create a urine test for hGH. In: 
Drug Testing and Analysis. Vol 1. ; 2009:447-454. doi:10.1002/dta.96. 
64.  Longo C, Patanarut A, George T, et al. Core-shell hydrogel particles harvest, 
concentrate and preserve labile low abundance biomarkers. PLoS One. 
2009;4(3). doi:10.1371/journal.pone.0004763. 
65.  Magni R, Espina BH, Shah K, et al. Application of Nanotrap technology for high 
sensitivity measurement of urinary outer surface protein A carboxyl-terminus 
domain in early stage Lyme borreliosis. J Transl Med. 2015;13(1):346. 
doi:10.1186/s12967-015-0701-z. 
66.  Castro-Sesquen YE, Gilman RH, Galdos-Cardenas G, et al. Use of a Novel 
Chagas Urine Nanoparticle Test (Chunap) for Diagnosis of Congenital Chagas 
Disease. PLoS Negl Trop Dis. 2014;8(10). doi:10.1371/journal.pntd.0003211. 
67.  Ehrich JH, Horstmann RD. Origin of proteinuria in human malaria. Trop Med 
Parasitol. 1985;36(1):39-42. 
68.  Carroll MF. Proteinuria in Adults: a diagnostic approach. Am Fam Physician. 
2000;62(6). 
69.  Nand N, Aggarwal H, Sharma M, Singh M. Systemic Manifestations of Malaria. J 
Indian Acad Clin Med. 2001;2(3):189-194. 
70.  Ephraim RKD, Tashie W, Agbodzakey H, et al. Dipstick urinalysis findings in 
 
 56 
children with Plasmodium falciparum in the South Tongu District: A case-control 








1353 Greenwich Walk NE, Issaquah, WA 98029 
Phone: (206) 419-6357   E-Mail: assumpcao.nicole@gmail.com 
Education  
Johns Hopkins School of Public Health 
ScM Student – Molecular Microbiology and Immunology August 2014-September 2016 
GPA: 3.92 
Courses include: Principles of Immunology, Virology, Biology of Parasitism, Introduction to 
International Health, Statistical Methods in Public Health (4 terms), Epidemiologic Methods (3 
terms), Project Development for Primary Health Care in Developing Countries, Implementation 
and Sustainability of Community-based Health Programs, Environment and Health in Low and 
Middle Income Countries, Managing Non-Governmental Organizations in the Health Sector, 
Large-Scale Effectiveness Evaluations, and others.  
 
Santa Clara University 
Bachelor of Science  - Biology and Psychobiology, Summa cum Laude Sept. 2013 
GPA: 3.95 
Courses included: Anatomy, Physiology, Cellular and Molecular Biology, Medical Microbiology, 
Neurobiology, Neuropsychology 
Awards and Honors: 
Phi Beta Kappa Honors Society (2013), Psi Chi Honors Society (2011), Dean’s list 2010-2013; 
Susan Valeriote and Kenneth A. Goldman Family Endowed Scholarship (2013) 
Lakeside School – High School Diploma                                
June 2009 
Languages Spoken:  English, Portuguese (fluent), Spanish (working proficiency), Chinese 
(basic)   
Research Experience 
ScM Thesis Research      January-September 2016 
 Under the guidance of Dr. David Sullivan and Dr. Robert Gilman, performed tests to look 
for and quantify HRP2 protein in the urine of malaria-infected patients. 
 Worked collaboratively with Dr. Lance Liotta and Dr. Alessandra Luchini at George 
mason University to find a hydrogel nanoparticle to aid in concentration of HRP2 from 
urine samples with the hope of developing a more sensitive urine-based diagnostic test. 
Global Health Established Field Placement Award         June 2015-August 2015 
 Received award through Center for Global Health at Johns Hopkins to perform research 
at a field site in Iquitos, Peru. 
 Performed community surveys on water usage, utilizing cultural competency to  dialogue 
with community members and work collaboratively with fieldworkers.  
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 Performed basic scientific tests for water quality, to be matched up with survey data for 
epidemiologic study on risk exposure and diarrheal disease in a five-year cohort study of 
children in a periurban environment in the Amazon. 
Student Rotations             January 2015-June 2015 
 Performed PCR analysis on urine samples for detection of Strongyloides stercoralis DNA. 
 Generated cDNA and ssRNA for gene knockouts in mosquitoes, then created 
nanoparticles for feeding/injection.   
 Reared, manipulated, and injected mosquitoes to manipulate expression of genes 
relating to transmission of vector-borne diseases.  
Research Assistant – Santa Clara Biology Department June 2013-December 2013 
 Worked in the lab of Dr. Teresa Ruscetti and Dr. Christelle Sabatier examining the 
connection of microbiological organisms colonizing the gut of c. elegans and their 
behavior and neurobiology, leading research on the naturally colonizing bacteria in wild c. 
elegans and transit time of bacteria through c. elegans gut.  
o Developed an assay for collection of wild nematodes from soil using bacteria and 
chemoattractants.  
o Developed an assay to determine the bacterial content of the gut of c. elegans.  
o Practiced aseptic technique in husbandry of bacterial strains (including anaerobic 
bacteria). 
o Trained fellow research assistants in aseptic technique in plate pouring and 
formulation of reagents.  
Research Assistant – Efficient Learning and Memory Lab March 2011-August 2012 
 Ran participants and compiled data under Dr. Patricia Simone and Dr. Matthew Bell, 
researching the effect of massed and spaced learning paradigms on long-term retention 
across ages. 
 Maintained data spreadsheets and utilized Excel to perform basic data analysis.  
Presentations 
World Malaria Day – Johns Hopkins University    Spring 2016 
 Presented poster on preliminary findings regarding nanoparticle-mediated concentration 
of proteins in urine of malaria-infected patients 
Northern California American Society for Microbiology Meeting        Fall 2013 
 Presented poster on numerous research methods utilized to determine transit time of 
bacterial foods through c. elegans gut.  
Western Psychological Association Convention     Spring 2012 
 Presented in a symposium regarding theory of “massed” versus “spaced” learning 
paradigms and their effect on long-term memory retention with Efficient Learning and 
Memory Lab.  
California Cognitive Science Conference      Spring 2011 
 Held at the University of California at Berkeley. Poster presentation of data on massed 
and spaced learning with Efficient Learning and Memory Lab.  
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Western Psychology Conference for Undergraduate Research   Spring 2011 
 Held at Saint Mary’s College. Poster presentation of data on massed and spaced 
learning. 
Teaching Experience 
Teaching Assistant - Human Physiology          Fall 2015, Summer 2016 
 Helped students at the Johns Hopkins School of Nursing to learn and retain information 
pertinent to human physiology. This included answering student questions as well as 
grading discussion posts on a weekly basis.  
Peer Educator – Life Writing       Spring 2013 
 Helped facilitate autobiographical writing in Life Writing course taught by Juan Velasco, 
including discussing difficult life topics in one-on-one sessions with students.  
 Edited student work for clarity, grammatical errors, and flow. 
Teaching Assistant - Human Neuropsychology         Fall 2011 
 Compiled comprehensive reviews of challenging material for undergraduate students in a 
Neuropsychology course taught by Dr. Patricia Simone, simplifying complex concepts to 
make them more accessible to students. 
Volunteer Experience 
English Teacher – Casa de la Solidaridad   August 2012-December 2012 
 Taught English to children in a marginalized community outside San Salvador, El 
Salvador while studying material pertaining to issues of social justice in the community. 
 Maintained a friendly demeanor even in challenging situations and built strong 
relationships with Salvadoran community. 
 
 
